HCM
CRSP icon

Hodges Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Hodges Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$224K – 242
2021
Q3 		$224K Hold
2,000
– – 0.02% 228
2021
Q2 		$324K Buy
+2,000
New +$243K 0.04% 201
2020
Q1 		– Sell
-50,000
Closed -$3.04M – 192
2019
Q4 		$3.04M Buy
+50,000
New +$2.73M 0.4% 80

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Hodges Capital Management's CRSP Position: Q4 2021 in Review

Hodges Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 2,000 shares — an estimated $224K sold.

Hodges Capital Management first reported a position in CRSP in Q4 2019 and held it in 3 quarters. The position peaked at $3.04M in Q4 2019. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Hodges Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Hodges Capital Management sold 2,000 CRISPR Therapeutics shares in Q4 2021, an estimated $224K.
  • Hodges Capital Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 3 quarters.
  • Hodges Capital Management's CRISPR Therapeutics position peaked at $3.04M in Q4 2019.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Hodges Capital Management's 13F filing for Q4 2021, filed 7 Feb 2022.